CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Alpha MSH assaydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03451578
NCT03451578N/ACompleted
CompareCT.gov

The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease

Duke University·interventional·Posted Mar 1, 2018·Updated Dec 22, 2022

In Brief

A clinical study evaluating Alpha MSH assay for Advanced Dry Macular Degeneration. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Dry Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 1, 2018
Enrollment StartMar 6, 2018
Primary CompletionOct 19, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.3 years ago

Interventions

Alpha MSH assaydevice

Assay to detect levels of alpha MSH in intraocular fluid.